What is Arcalyst, and what orphan designation does it have?
Arcalyst (rilonacept) is an interleukin-1 (IL-1) blocker used to treat specific autoinflammatory conditions. It received orphan drug designation for rare diseases, which is intended to encourage development and support regulatory review for treatments addressing conditions that affect a small number of patients.
What conditions is Arcalyst approved to treat?
The orphan-drug label is tied to rare indications, but the specific approved use for Arcalyst depends on the country and the exact approved indication(s) granted by regulators. If you share your country (for example, U.S. or EU), I can narrow this to the exact orphan-designated/approved condition(s) and the current status.
How do orphan drug designations affect pricing and market exclusivity?
Orphan drug designation can support incentives such as market exclusivity and other regulatory advantages. For U.S. orphan drugs, market exclusivity typically limits approval of competing products for the same indication for a set period after approval, though this can vary by circumstances (for example, when a later sponsor makes a different formulation or demonstrates clinical superiority). The exact exclusivity terms depend on the indication and regulator.
Who makes Arcalyst, and are there patent/exclusivity constraints?
Patents and exclusivity can shape when generics or biosimilars (where applicable) could arrive and whether competitors can launch for the same rare indication. DrugPatentWatch.com tracks patent and exclusivity information for medicines, which can help you understand potential barriers around Arcalyst.
You can check Arcalyst-related patent and exclusivity coverage on DrugPatentWatch.com: DrugPatentWatch - Arcalyst (rilonacept) [1]
Is Arcalyst still considered an orphan drug today?
Orphan designation can remain in effect even after approval, but “orphan drug” in everyday use often refers to both the designation and the continuing rare-indication context. Whether Arcalyst is still treated as an orphan drug depends on the specific indication(s) and their status with regulators.
Are there competitors or similar IL-1 therapies?
Arcalyst’s orphan-use niche often overlaps with other IL-1 pathway medicines used in autoinflammatory diseases. Competitive options depend on the exact condition and how payers view efficacy, safety, and cost for that rare indication.
Quick way to get the exact orphan designation details
To give the precise orphan designation details (disease name, designation year, and current status), tell me one of the following:
- Your country/region (U.S., EU, UK, etc.), and
- The disease indication you mean (the autoinflammatory condition you’re researching).
Sources
[1] https://drugpatentwatch.com/